PubMed Health⌕ Search

Biomedical subjects

Brad Bolon

Publications and source records attributed to Brad Bolon.

25 records · Page 2Linked to original sources

Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis.

OBJECTIVE: To assess the effect of different dosages and treatment schedules of osteoprotegerin (OPG) on joint preservation in an experimental model of adjuvant-induced arthritis (AIA). METHODS: Male Lewis rats with AIA (6-8 per group) were treated with a subcutaneous bolus of recombinant human OPG according to one of the following schedules: daily OPG (an efficacious regimen) starting at disease onset (days 9-15), early intervention (days 9-11), delayed intervention (days 13-15), and extended therapy (days 9-22). Inflammation (hind paw swelling) was quantified throughout the clinical course; osteoporosis (bone mineral density [BMD], by quantitative dual x-ray absorptiometry) and morphologic appraisals of inflammation, bone damage, intralesional osteoclasts (by semiquantitative histopathologic scoring), and integrity of the articular cartilage matrix (by retention of toluidine blue stain) were determined in histology sections of arthritic hind paws. RESULTS: OPG provided dose- and schedule-dependent preservation of BMD and periarticular bone while essentially eliminating intralesional osteoclasts. Dosages > or = 2.5 mg/kg/day preserved or enhanced BMD and prevented essentially all erosions. A dosage of 4 mg/kg/day protected joint integrity to a comparable degree when given for 7 (days 9-15) or 14 (days 9-22) consecutive days. At this dosage, early intervention (days 9-11) was twice as effective as delayed intervention (days 13-15) at preventing joint dissolution. Erosions and osteoclast scores were greatly decreased for 26 days (measured from the first treatment) after 7 or 14 daily doses of OPG (4 mg/kg/day). OPG treatment also prevented loss of cartilage matrix proteoglycans, an indirect consequence of protecting the subchondral bone. No OPG dosage or regimen alleviated weight loss, inflammation, or periosteal osteophyte production. CONCLUSION: These data indicate that OPG preserves articular bone and (indirectly) articular cartilage in arthritic joints in a dose- and schedule-dependent manner, halts bone erosion when given at any point during the course of arthritis, produces sustained antierosive activity after a short course, and is most effective when initiated early in the disease.

Absorptiometry, Photon↗

Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis.

OBJECTIVE: To assess the capacities of the cytokine inhibitors interleukin-1 receptor antagonist (IL-1Ra; anakinra) and PEGylated soluble tumor necrosis factor receptor I (PEG sTNFRI; pegsunercept) to suppress neovascularization. METHODS: A corneal angiogenesis assay was performed by implanting nylon discs impregnated with an angiogenic stimulator (basic fibroblast growth factor or vascular endothelial growth factor) into one cornea of female Sprague-Dawley rats. Animals were treated with IL-1Ra or PEG sTNFRI for 7 days, after which new vessels were quantified. In a parallel study, male Lewis rats with mycobacteria-induced adjuvant-induced arthritis were treated with IL-1Ra or PEG sTNFRI for 7 days beginning at disease onset, after which scores for inflammation and bone erosion as well as capillary counts were acquired from sections of arthritic hind paws. RESULTS: Treatment with IL-1Ra yielded a dose-dependent reduction in growth factor-induced corneal angiogenesis, while PEG sTNFRI did not. IL-1Ra, but not PEG sTNFRI, significantly reduced the number of capillaries in arthritic paws, even though both anticytokines reduced inflammation and bone erosion to a similar degree. CONCLUSION: These data support a major role for IL-1, but not TNFalpha, in angiogenesis and suggest that an additional antiarthritic mechanism afforded by IL-1 inhibitors, but not anti-TNF agents, is the suppression of the angiogenic component of pannus.

Animals↗

Progression of alachlor-induced olfactory mucosal tumours.

Alachlor is an herbicide used primarily in the production of corn (maize), peanuts, and soybeans and is associated with cancer of the nasal cavity, thyroid, and stomach in rats. Previous work from our laboratory demonstrated that the nasal cavity tumours originate from the olfactory mucosa, and that neoplasms were present following 6 months of exposure (126 mg/kg/day in the diet). The studies presented herein were conducted to determine more precisely the earliest time point at which alachlor-induced tumours were present, and to describe the histological changes that occur en route to tumour formation. We determined that dramatic histological changes, including respiratory metaplasia of the olfactory mucosa, were present following 3 months of exposure, and the earliest alachlor-induced olfactory mucosal tumours were detected following 5 months of treatment. Because alachlor is positive in short-term mutagenicity assays with olfactory mucosal activation, and because of the relatively short time-to-tumour formation observed with alachlor, we also conducted a 'stop' study in which rats were treated with alachlor for 1 month and then held without further treatment for an additional 5 months. This study demonstrated that abbreviated alachlor exposure did not result in subsequent tumour formation within the 6-month observation period.

Acetamides↗

Atmospheric waste isoflurane concentrations using conventional equipment and rat anesthesia protocols.

Chronic, low-level exposure of health care professionals to waste anesthetic gases has been linked to increased incidences of neurologic and reproductive dysfunction, hepatic and renal toxicity, and neoplasia. The present study assessed the potential for waste anesthetic gas exposure to researchers administering isoflurane to rats by using standard delivery systems and conventional anesthesia protocols. Well-maintained bench-top precision isoflurane vaporizers were equipped with two circuits (a nonrebreathing one hooked to a modified Bain facemask, and the other to an induction box) attached to commercially available, activated charcoal canisters (passive gas scavenging). The isoflurane concentration was varied from 1% to 5%, while the oxygen flow rate was either 1 or 2.5 L/min. Real-time atmospheric isoflurane levels were assessed by using a portable infrared spectrophotometer. When euthanized female sentinel CD rats were positioned in the facemask loop, isoflurane emissions at the mask rat interface, breathing zone, and exhaust port of scavenging canisters were increased in proportion to the isoflurane concentration and oxygen flow rates as well as the amount of gas directed through the facemask circuit. Isoflurane was detected in the anesthetist s breathing zone only if the entire carrier gas flow was directed to the facemask loop. The background isoflurane level rose to 0.5 ppm after 75 min of continuous bench-top operation in a room with 22 air exchanges hourly but did not escalate if the anesthesia unit--or at least the gas-scavenging canister--was placed in a fume hood, or if the system was used in a room with 42 hourly air changes. Isoflurane efflux via the exhaust ports exceeded 5 ppm in 31% of gas-scavenging canisters that had not reached their maximum use life (as defined by the manufacturer's specifications); in a parallel prospective study, isoflurane was emitted from 88% of canisters by the time that they had reached 50% of their specified lifespan. These data indicate that (1) isoflurane emissions likely will occur at trace levels in laboratory animal facilities even when well-maintained precision isoflurane vaporizers equipped with conventional activated charcoal (passive) gas-scavenging units are used and (2) exposure to anesthetic pollution can be mitigated substantially by selecting low-flow anesthesia regimens, improving gas-scavenging practices, and optimizing the configurations of the delivery system and work area.

Air Pollutants, Occupational↗

The candidate neuroprotective agent artemin induces autonomic neural dysplasia without preventing peripheral nerve dysfunction.

Artemin (ART) signals through the GFR alpha-3/RET receptor complex to support sympathetic neuron development. Here we show that ART also influences autonomic elements in adrenal medulla and enteric and pelvic ganglia. Transgenic mice over-expressing Art throughout development exhibited systemic autonomic neural lesions including fusion of adrenal medullae with adjacent paraganglia, adrenal medullary dysplasia, and marked enlargement of sympathetic (superior cervical and sympathetic chain ganglia) and parasympathetic (enteric, pelvic) ganglia. Changes began by gestational day 12.5 and formed progressively larger masses during adulthood. Art supplementation in wild type adult mice by administering recombinant protein or an Art-bearing retroviral vector resulted in hyperplasia or neuronal metaplasia at the adrenal corticomedullary junction. Expression data revealed that Gfr alpha-3 is expressed during development in the adrenal medulla, sensory and autonomic ganglia and their projections, while Art is found in contiguous mesenchymal domains (especially skeleton) and in certain nerves. Intrathecal Art therapy did not reduce hypalgesia in rats following nerve ligation. These data (1) confirm that ART acts as a differentiation factor for autonomic (chiefly sympathoadrenal but also parasympathetic) neurons, (2) suggest a role for ART overexpression in the genesis of pheochromocytomas and paragangliomas, and (3) indicate that ART is not a suitable therapy for peripheral neuropathy.

Adult↗

Use of genetically engineered mice in drug discovery and development: wielding Occam's razor to prune the product portfolio.

Genetically engineered mice (GEMs) that either overexpress (transgenic) or lack (gene-targeted, or "knock-out") genes are used increasingly in industry to investigate molecular mechanisms of disease, to evaluate innovative therapeutic targets, and to screen agents for efficacy and/or toxicity. High throughput GEM construction in drug discovery and development (DDD) serves two main purposes: to test whether a given gene participates in a disease condition, or to determine the function(s) of a protein that is encoded by an expressed sequence tag (EST, an mRNA fragment for a previously uncharacterized protein). In some instances, phenotypes induced by such novel GEMs also may yield clues regarding potential target organs and toxic effects of potential therapeutic molecules. The battery of tests used in phenotypic analysis of GEMs varies between companies, but the goal is to define one or more easily measured endpoints that can be used to monitor the disease course--especially during in vivo treatment with novel drug candidates. In many DDD projects, overt phenotypes are subtle or absent even in GEMs in which high-level expression or total ablation of an engineered gene can be confirmed. This outcome presents a major quandary for biotechnology and pharmaceutical firms: given the significant expense and labor required to generate GEMs, what should be done with "negative" constructs? The 14th century philosophical principle known as Occam's razor-that the simplest explanation for a phenomenon is likely the truth-provides a reasonable basis for pruning potential therapeutic molecules and targets. In the context of DDD, Occam's razor may be construed to mean that correctly engineered GEMs lacking obvious functional or structural phenotypes have none because the affected gene is not uniquely essential to normal homeostasis or disease progression. Thus, a "negative" GEM construct suggests that the gene under investigation encodes a ligand or target molecule without significant therapeutic potential. This interpretation indicates that, at least in a market-driven industrial setting, such "negative" projects should be pruned aggressively so that resources may be redirected to more promising DDD ventures.

Animals↗